Replimune Group's RP1 oncolytic virus therapy faced an FDA rejection, raising concerns about the platform's viability in ...

National investment management authority Danantara Indonesia has pledged Rp1.5 trillion (US$92 million) to buy up farmers’ ...

In an open letter, 22 experts who designed and ran Replimmune’s Phase III IGNYTE trial answered the FDA’s issues, as outlined ...

Shares of Replimune (NASDAQ:REPL) plunged ~38% in the premarket on Monday after Stat News reported that the FDA’s top ...

The FDA's top regulator of cancer drugs played a key role in the rejection of a skin cancer therapy from Replimune Group, ...

Key Points On July 22, 2025, the U.S. Food and Drug Administration issued a Complete Response Letter for RP1, delaying potential commercialization and revenue. Research and development expenses ...

Detailed price information for Replimune Group Inc (REPL-Q) from The Globe and Mail including charting and trades.

The CRL was given because the FDA did not consider the phase 1/2 IGNYTE trial to be an adequate and well-controlled clinical investigation to provide substantial evidence to support approval ...

Retail trader buzz around Replimune Group surged Wednesday after Cantor Fitzgerald upgraded the stock to ‘Overweight’ from ...

The Ministry of Higher Education, Science, and Technology (Kemdiktisaintek) has allocated Rp1.8 trillion (US$107 million) to ...

Dr. Gino Kim In, a medical oncologist with Keck Medicine of USC, is one of the lead investigators on the trial. Keck Medicine of USC RP1 was reported to be well-tolerated among the participants.

Unlike its natural predecessor, RP1 does not cause herpes. The U.S. Food and Drug Administration approved RP1 for review in patients with advanced melanoma that was not responding to immunotherapy ...